Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | COVID-19: treating CLL patients

Constantine Tam • 13 May 2020
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors Ibrutinib

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the management of chronic lymphocytic leukemia (CLL) patients during the COVID-19 pandemic. Specifically, Dr Tam debates the use of BTK inhibitors in patients positive for SARS‐CoV‐2. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Constantine Tam

1:13
ALPINE trial update: zanubrutinib continues to show superior efficacy to ibrutinib in CLL
Constantine Tam • 11 Dec 2023
2:06
The potential of BGB-16673, a BTK degrader, for the treatment of R/R B-cell malignancies
Constantine Tam • 11 Dec 2023
1:52
SYMPATICO: Primary analysis results of ibrutinib plus venetoclax for patients with R/R MCL
Constantine Tam • 11 Dec 2023
2:36
Sonrotoclax plus zanubrutinib combination shows promise in treatment-naïve CLL/SLL
Constantine Tam • 11 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals